AXIM Biotechnologies, Inc.
Moat Score — AXIM Biotechnologies, Inc.
Total Moat Score
4 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Holds two FDA-cleared 510(k) diagnostic tests (Lactoferrin, IgE), three allowed patents, roughly seven pending patent applications, and two registered trademarks, but commercial monetization of this IP remains minimal and unproven. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | No evidence of a structural cost advantage; the company is a sub-scale, cash-starved operator competing against far larger, better-resourced diagnostics companies like Quidel/QuidelOrtho and TearLab. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | Revenue is in the tens of thousands of dollars per quarter and sold through third-party distributors, with no demonstrated ability to set or defend pricing in its niche. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | A point-of-care diagnostics hardware/cassette business with no network effects between users, clinics, or data. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | The reader-plus-disposable-cassette model creates a mild recurring-purchase dynamic once a reader is placed in a clinic, but the installed base is too small to constitute a real switching-cost moat. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Operates in a narrow, FDA-gated niche with few approved competitors, but AXIM itself lacks the scale to be considered an entrenched incumbent, and the company deregistered from SEC reporting in December 2024 amid severe liquidity distress. |